MiR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 2, 2013, Pages 80-86

  Zhu, Xiaolan ^a   Li, Yuefeng ^a   Shen, Huiling ^a   Li, Hao ^a   Long, Lulu ^a   Hui, Lulu ^a   Xu, Wenlin ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

MiR 137; Multidrug resistance; Y box binding protein 1

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MIRN137 MICRORNA, HUMAN; Y BOX BINDING PROTEIN 1; YBX1 PROTEIN, HUMAN;

ARTICLE; CELL STRAIN MCF 7; DRUG ANTAGONISM; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MCF-7 CELLS; MICRORNAS; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME; Y-BOX-BINDING PROTEIN 1;

MLCS; MLOWN;

EID: 84881240976     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms099     Document Type: Article

References (36)

1. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev 2006, 5: 219-234.
2. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2: 48-58.
3. Singh P, Kaur J, Kaur P and Kaur S. Search for MDR modulators: design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg2+. Bioorg Med Chem 2009, 17: 2423-2427.
4. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006, 13: 1859-1876.
5. Borowski E, Bontemps-Gracz MM and Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005, 52: 609-627.
6. Matsumoto K and Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 1998, 8: 318-323.
7. Saji H, Toi M, Saji S, Koike M, Kohno K and Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003, 190: 191-197.
8. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K and Schmitt M, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002, 97: 278-282.
9. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H and Uchiumi T, et al. Enhanced co-expression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 1999, 83: 732-737.
10. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T and Kohno K. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 2004, 93: 287-291.
11. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S and Gleave ME, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004, 59: 337-349.
12. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K and Yasumoto K, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001, 7: 3151-3155.
13. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K and Mapara MY, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997, 3: 447-450.
14. Chattopadhyay R, Das S, Maiti AK, Boldogh I, Xie J, Hazra TK and Kohno K, et al. Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. Mol Cell Biol 2008, 28: 7066-7080.
15. Shen H, Xu W, Luo W, Zhou L, Yong W, Chen F and Wu C, et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol 2011, 39: 558-569.
16. Calin GA and Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006, 25: 6202-6210.
17. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG and Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/ P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008, 76: 582-588.
18. Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY. miR-21 mediated tumor growth. Oncogene 2007, 26: 2799-2803.
19. Li H, Hui L and Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochem Biophys Sin 2012, 44: 269-277.
20. Zhu X, Li H, Long L, Hui L, Chen H, Wang X and Shen H, et al. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochem Biophys Sin 2012, 44: 519-526.
21. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008, 7: 2152-2159.
22. Malugin A, Kopeckova P and Kopecek J. HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway. Mol Pharm 2004, 1: 174-182.
23. Chen X, Wang J, Shen H, Lu J, Li C, Hu DN and Dong XD, et al. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci 2011, 52: 1193-1199.
24. Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q and Chen J, et al. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer 2011, 128: 1269-1279.
25. van Jaarsveld MT, Helleman J, Berns EM and Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010, 42: 1282-1290.
26. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K and Wagar N, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010, 79: 817-824.
27. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI and Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010, 127: 1785-1794.
28. Pan YZ, Morris ME and Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009, 75: 1374-1379.
29. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR and Goel A. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010, 70: 6609-6618.
30. Chen Q, Chen X, Zhang M, Fan Q, Luo S and Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 2011, 56: 2009-2016.
31. Kozaki K, Imoto I, Mogi S, Omura K and Inazawa J. Exploration of tumorsuppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008, 68: 2094-2105.
32. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M and Vandenberg SR, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008, 6: 14.
33. Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW and Taioli E. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis 2010, 31: 864-870.
34. Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L and Seethala RR, et al. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer 2010, 117: 1454-1462.
35. Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y and He F. MiR-137 Targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One 2012, 7: e39102.
36. Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H and Maeno K, et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 2005, 11: 8837-8844.